Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible.
![Loxo Oncology logo](/files/LOGO/1581720-LOXO.png)
Company profile
Ticker
LOXO
Exchange
Website
CEO
Joshua H. Bilenker
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
LOXO stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
25 Feb 19
EFFECT
Notice of effectiveness
22 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
8-K
Completion of Acquisition or Disposition of Assets
15 Feb 19
POSASR
Automatic shelf registration (post-effective amendment)
15 Feb 19
Latest ownership filings
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Loxo Oncology, Inc.
8 Jan 20
SC 13D/A
Loxo Oncology, Inc.
15 Feb 19
SC 13D/A
Beneficial ownership report (amended)
15 Feb 19
4
Naarden Jacob Van
15 Feb 19
4
Nisha Nanda
15 Feb 19
4
Avi Z. Naider
15 Feb 19
4
TIMOTHY M MAYLEBEN
15 Feb 19
4
Lori Anne Kunkel
15 Feb 19
4
Steve Harr
15 Feb 19
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|